Table 1.
Baseline characteristics.
| Parameter | N = 72 (%) |
|---|---|
| Age | |
| ≤65 years | 44 (61) |
| >65 years | 28 (39) |
| Sex | |
| female | 23 (32) |
| male | 49 (68) |
| ypN stage | |
| N- | 48 (67) |
| N+ | 24 (33) |
| cTNM stage | |
| I | 1 (1) |
| II | 29 (40) |
| III | 37 (52) |
| IV | 5 (7) |
| Histologic grade | |
| I | 1 (1) |
| II | 61 (87) |
| III | 8 (12) |
| NA | 2 |
| Dworak tumor regression grade | |
| 0 | 3 (4) |
| I | 16 (22) |
| II | 25 (35) |
| III | 20 (28) |
| IV | 8 (11) |
| Microsatellite status | |
| MSS | 56 (98) |
| MSI | 1 (2) |
| NA | 15 |
| CRT backbone | |
| 5-FU or capecitabine | 29 (40) |
| 5-FU + oxaliplatin or capecitabine + oxaliplatin | 43 (60) |
| NAR score | |
| low | 11 (15) |
| intermediate | 36 (50) |
| high | 25 (35) |
| Adjuvant chemotherapy | |
| yes | 36 (52) |
| no | 33 (48) |
| NA | 3 |
CRT: chemoradiotherapy; MSI: microsatellite instability; MSS: microsatellite stability; NA: not available, NAR score: neoadjuvant rectal score; PD-L1: programmed death-ligand 1.